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Abstract
Background: Formulae for infants with cow's milk protein allergy (CMA) should be based on
extensively hydrolysed protein. 'Extensively' however is not strictly defined. Differences in
molecular weight and peptide chain length may affect its clinical outcome. We studied the safety of
a new extensively hydrolysed casein based formula (Frisolac Allergycare®: FAC) for children with
IgE mediated CMA.
Methods: Thirty children, aged 1.5 – 14.8 years old (median 4.9 years) with persistent CMA were
enrolled in this double-blind reference product (Nutramigen®: NUT) controlled crossover study.
All had positive skin prick tests (SPT) and IgE mediated allergy, showing immediate reactions after
ingestion of small amounts of milk. Twenty-five children also had positive radio allergen sorbent
tests (RAST) to cow's milk. Formulae provided consisted of 80% elementary formula in
combination with 20% reference or test product. Crossover periods lasted for two weeks. From
both products molecular weight (MALDI-TOF method and HPLC) and peptide chain length
distribution (adapted Edman degradation) were determined.
Results: Maximum molecular weights of NUT and FAC are 2.1 and 2.56 kDa, respectively. The
contribution of free amino acids and small peptides <0.5 kDa is 46% for FAC and 53% for NUT.
About 50% of the protein fraction of both products consists of peptides longer than four amino
acids. Three children did not complete the study. The other children all tolerated FAC very well;
no adverse reactions were reported.
Conclusions: The new extensively hydrolysed casein-based formula (FAC) can safely be used in
children with IgE mediated cow's milk allergy.
Background
Cow's milk protein allergy (CMA) is an increasing prob-
lem in infancy, and a result from an abnormal immuno-
logic reaction to cow's milk protein [1]. About 3% of all
new-borns will suffer from CMA within the first year of
life. Although breast milk is the best to provide, up to
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1.5% of breast-fed infants will develop CMA [2]. Treat-
ment of CMA in infants and young children means total
avoidance of cow's milk and use of 'hypoallergenic' for-
mulae. It has been stressed by both the European Society
for Paediatric Allergy and Clinical Immunology (ESPACI)
and the European Society for Paediatric Gastroenterology,
Hepatology, and Nutrition (ESPGHAN) that only exten-
sively hydrolysed formulae should be used in IgE mediat-
ed CMA owing to their proven safety and
hypoallergenicity [3–6]. Partially hydrolysed formulae
should be avoided in infants having CMA due to the un-
acceptable frequency of adverse, at times even severe, re-
actions associated with their ingestion [4,7–9]. However,
these hydrolysates may be useful in prevention of CMA in
high-risk infants as has been shown in four recently pub-
lished studies [10–13]. The terms 'partially' and 'exten-
sively' are not well defined. Although molecular weight is
an important classifier, studies have shown that products
with hydrolysates of comparable molecular weight may
have different preventive or treatment effects [12] or is of
less predictive value than suggested [11]. Other character-
istics, such as peptide chain length distribution may be
necessary to judge the effectiveness of the protein hydro-
lysate. However, this has to be studied and for the time be-
ing the only way to determine the safety of a hydrolysate-
based product is to test it in those with CMA as also indi-
cated by the American Academy of Pediatrics [7] and the
European Community [14]. The aim of this double blind,
cross-over study was to determine whether a new exten-
sively hydrolysed casein based formula (Frisolac Allergy-
care®; FAC), with about 22% free amino acids and a
maximum molecular weight of 2.56 kDa can be adminis-
tered safely to children with IgE mediated CMA. As refer-
ence product Nutramigen® (NUT) was used.
Methods
Peptide characteristics of the used products were studied
by three methods. Determination of absolute molecular
weight was done by the matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry method
(MALDI-TOF), a rapid and sensitive quantitative method
with high resolution for peptides as described by
Kaufmann [15] and Soerpyapranata [16]. Molecular size
distribution was measured with high-performance gel-
permeation chromatography (HP-GPC, Superdex 75
HR10/30 column) with a phosphate-sulphate buffer (pH
6.65), and spectrophotometric detection at 20 nm. For
calibration, the following proteins and peptides were
used: bovine serum albumin (68 kDa), bovine -lactalbu-
min (14.40 kDa), cytochrome C (12.32 kDa), insulin A
oxidized (2.53 kDa), bradikinin (1.06 kDa), Arg-Lys-Asp-
Val-Tyr (0.68 kDa), Pro-Phe-Gly-Lys (0.447 kDa), Thr-
Tyr-Ser (0.369 kDa), Tyr-Arg (0.337 kDa), and TRP-Gly
(0.261 kDa). This HP-GPC method is often used as an al-
ternative for molecular weight measurement. An accurate
distribution of peptide chain length was obtained by us-
ing an adapted Edman degradation [17].
Thirty children under treatment (23 boys and 7 girls) were
included. Characteristics of participants are described in
Table 1. All children showed immediate IgE mediated hy-
persensitivity reactions after challenge with or ingestion of
small amounts of cow's milk at the time of inclusion. The
reactions to cow's milk were exacerbation of the pre-exist-
ing eczema (morbilliform-like rash), oral allergy syn-
drome, wheeze and sneeze, vomiting, rhino-
conjunctivitis and even anaphylactic reaction.
Skin prick tests (SPT) were performed using extracts of
cow's milk. Results were evaluated after 15 minutes. A
positive test was classified as a weal of 3 mm or larger. His-
tamine (10 mg/ml) and a diluent solution were used as
positive and negative controls respectively. All children
had positive SPT to cow's milk and 25 of 30 also had pos-
itive radio allergen sorbent test (RAST) to cow's milk. All
children used extensively hydrolysed formulae from dif-
ferent manufacturers. None of them had signs of allergy.
The study had a cross-over, double-blind reference prod-
uct controlled design. To guarantee the double-blind char-
acter of the study, the tested formulae were mixed with an
elementary formula, home-made and prescribed by the
Wilhelmina Children's Hospital in severe CMA, in a ratio
of 80% elementary formula and 20% test formula. Orga-
noleptic tests (taste, smell and outer appearance) by inde-
pendent inspectors showed that in this ratio the test
formula, FAC (Friesland Nutrition, Leeuwarden, The
Netherlands) was indistinguishable from the reference
product NUT (Mead Johnson, USA) which is been widely
used for CMA treatment. The formulae were mixed under
aseptic conditions and coded.
After informed consent was obtained, the children were
randomly assigned to group A or B. Group A started with
the test formula in the first period (weeks 1 and 2) and
was fed with the reference product the second period
(weeks 3 and 4). Group B started with the reference for-
mula and changed to the test formula the second period.
In case children had had an anaphylactic reaction in the
past to cow's milk, an open challenge with the test formu-
la was performed at the day care centre of the Wilhelmi-
na's Children's Hospital. When no adverse reaction
occurred during challenge, the test formula was consid-
ered to be safe to ingest by the child during this study.
A weekly questionnaire containing questions about skin,
gastro-intestinal tract, respiratory tract, behaviour, fever,
and anaphylaxis was answered. Questions were scored 1
point when answered positive, 0.5 points when answered
, and 0 points when answered negative. QuestionnaireBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/10
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scores were analysed according to the Wilcoxon signed-
rank test, testing the hypothesis that no difference exists
between the test and the placebo formula. P < 0.05 was
considered statistically significant.
This study was approved by the Medical Ethical Commit-
tee of the University Hospital Utrecht, The Netherlands.
Results
The absolute maximum molecular weights (MALDI-TOF)
as determined for the protein fraction of the complete
products were 2.108 kDa and 2.562 kDa for NUT and
FAC, respectively. Remarkable was the difference between
the molecular weight of the hydrolysate used in FAC and
the final product FAC. The maximum molecular weight
increased from 1.613 kDa to 2.562 kDa. For NUT this was
not studied since we did not have the hydrolysate used in
this product.
Molecular weight profile and peptide length profile of the
hydrolysates are shown in Figures 1, 2 and 3. Figures 1 and
2 show no relevant differences in absolute molecular
weight between FAC and NUT. In peptide length profile
(Figure 3), the test hydrolysate showed to have more di-
and tripeptides and a somewhat lower free amino acid
content compared with NUT.
Twenty-seven of the 30 children completed the study. Of
the three children who failed to complete the study, two
children refused to drink the formula after two weeks and
one child had an exacerbation of dermatitis in the NUT
period.
Group A comprised 12 children and group B 15 children.
Distribution of age, gender, RAST, atopic disease and
questionnaire score at start of the study between the two
groups was comparable (Table 2). None of the 27 chil-
Figure 1
Molecular weight profile of the hydrolysate used in Frisolac Allergycare® (FAC). The molecular weight profile is determined
with the MALDI-TOF method as described by Schols [19] and Kaufmann [15] and Soeryapranata [16].
Panel ABMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/10
Page 4 of 7
(page number not for citation purposes)
dren showed an adverse reaction or exacerbation of the al-
lergic symptoms to the test formula.
The mean score after using the reference formula NUT was
1.28 (S.D.: 1.87) and after using the test formula FAC 0.89
(S.D.: 1.28). Analysis according to the Wilcoxon signed-
rank test indicated that the two formulae did not differ
significantly (p = 0.135).
Discussion
In this study, FAC is as effective as NUT which indicates
that Frisolac Allergycare is suitable for infants and chil-
dren with CMA. Both products have maximum molecular
peptide weights lower than 3 kDa (Figure 1 and 2), a mo-
lecular size that is thought to have a low probability on at
least two antibody binding sites which is a prerequisite for
inducing an allergic response [19]. Based on the peptide
length distribution (Figure 3), FAC contains less free ami-
no acids, which is in favour of taste.
A first indication of safe use of the FAC hydrolysate in a
study with children with proven CMA was based on pre-
ceding animal studies (not published). No development
of antibodies specific for the hydrolysate was seen in mice
and rats, whereas no active systemic anaphylaxis could be
initiated in guinea pigs.
Although both products FAC and NUT had molecular
weights less than 3 kDa based on our methods, Rosendal
and Barkholt [18] showed that even extensively hydro-
lyzed formulae like NUT may contain peptide fractions of
molecular weight above 5 kDa as determined by SDS-
PAGE. They suggest that this may explain the rare occa-
sions of allergic reactions on these formulae. However, no
epitopes for anti-whey, -casein or -soybean protein anti-
bodies were detected. They also found small amounts of
-lactoglobulin in NUT, based on sandwich ELISA al-
though the principal protein source used is casein. The
presence of a whey protein in such a product may be ex-
plained by co-precipitation during isolation of the casein
fraction, or contamination during processing, it also may
point to an overestimation by ELISA. Therefore, the accu-
rate way to study a hydrolyzed formula is in a clinical
study with cow's milk protein allergic patients.
A higher maximum molecular weight in the final product
FAC compared with the used hydrolysate may be ex-
plained by aggregation of smaller peptides to larger parti-
cles, or contamination despite careful processing. It is
known that due to heat treatment, enzymatic hydrolysis,
and changes in protein structure aggregation sites such as
SH-groups may become available for the formation of S-S
bridges [19]. Rosendal and Barkholt [18] however, did
not find substantial amounts of aggregated or polymer-
ized material in 12 products with different degrees of hy-
drolysis.
A point of dicussion is that all children did well on the ref-
erence products before inclusion. In this way, children
that may not tolerate the small amounts of larger peptides
that may be present in the reference product were exclud-
ed.
Table 1: Patients' characteristics
Number 30
Age 19 – 176 months
Median age 51 months
Gender 23 boys, 7 girls
Atopic disease
Eczema 23
Asthma/wheezing 17
Gastro-intestinal symptoms 3
 2 signs 10
Positive RAST 25
Positive SPT 30
Symptoms-after challenge with cow's milk
Oral allergy 7
Wheeze 5
Urticaria 8
Exacerbation eczema (rash) 10
Angio-edema 3
Vomiting 2
Rhino-conjunctivitis 2
Anaphylaxis 1
 2 symptoms 8BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/10
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Figure 2
Molecular weight profile of Nutramigen® (NUT). The molecular weight profile is determined with the MALDI-TOF method as
described by Schols [19] and Kaufmann [15] and Soeryapranata [16].
Table 2: Group characteristics at the start of the study
Group A Group B
Number 12 15
Mean age (months) 64.4 64.0
Gender (boys/girls) 10/2 11/4
RAST (positive/negative) 10/2 12/3
Atopic disease (number):
Dermatitis 5 5
Asthma 2 6
Dermatitis and asthma 4 3
Dermatitis and GI-symptoms 1 1
Mean questionnaire score at start of the study 1.98 1.78
Panel BBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/10
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Another point of discussion may be the inclusion of older
infants in this study. However, to our opinion these chil-
dren with a persistent CMA can be considered to be a
more vulnerable group.
Conclusion
Because children with persistent and proven IgE mediated
CMA did not show adverse reactions after consumption of
a new extensively hydrolyzed formula (Frisolac Allergy-
care®), this formula can be regarded as safe for this target
population.
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